Want to see CYRX full AI Analyst Report?
Segment Adjusted EBITDA Breakdown
Breaks down profitability by business unit after one-time items, highlighting which parts of the company generate the strongest margins and where operational improvements or investment could most impact overall earnings and cash generation.Life Sciences Products is the steady EBITDA engine—consistent, expanding contribution from MVE and new products—while Life Sciences Services is erratic, swinging between small profits and losses as onboarding cycles, trial cadence and capacity investments bite. Management’s Q1 commentary (services revenue +18%, product momentum and a $2.2M YoY adjusted‑EBITDA improvement) validates improving corporate profitability, but the path to H2 2026 positivity remains execution‑dependent given product‑mix margin variability and multi‑quarter ramps for IntegraCell and new facilities.
Date | Life Sciences Services | Life Sciences Products |
|---|---|---|
Jun 30, 2026 | $1.65M | $4.29M |
Mar 31, 2026 | -$96.00K | $3.67M |
Dec 31, 2025 | -$282.00K | $3.28M |
Sep 30, 2025 | $1.60M | $3.50M |
Jun 30, 2025 | -$54.00K | $4.01M |
Mar 31, 2025 | -$2.48M | $3.51M |
Dec 31, 2024 | $154.00K | $4.25M |
Sep 30, 2024 | -$1.55M | $2.83M |
Jun 30, 2024 | -$4.02M | $3.51M |
Mar 31, 2024 | -$4.94M | $2.12M |